106 reports of this reaction
1.3% of all NORGESTIMATE AND ETHINYL ESTRADIOL reports
#18 most reported adverse reaction
PULMONARY EMBOLISM is the #18 most commonly reported adverse reaction for NORGESTIMATE AND ETHINYL ESTRADIOL, manufactured by Teva Pharmaceuticals USA, Inc.. There are 106 FDA adverse event reports linking NORGESTIMATE AND ETHINYL ESTRADIOL to PULMONARY EMBOLISM. This represents approximately 1.3% of all 7,959 adverse event reports for this drug.
Patients taking NORGESTIMATE AND ETHINYL ESTRADIOL who experience pulmonary embolism should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PULMONARY EMBOLISM is a less commonly reported adverse event for NORGESTIMATE AND ETHINYL ESTRADIOL, but still significant enough to appear in the safety profile.
In addition to pulmonary embolism, the following adverse reactions have been reported for NORGESTIMATE AND ETHINYL ESTRADIOL:
The following drugs have also been linked to pulmonary embolism in FDA adverse event reports:
PULMONARY EMBOLISM has been reported as an adverse event in 106 FDA reports for NORGESTIMATE AND ETHINYL ESTRADIOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
PULMONARY EMBOLISM accounts for approximately 1.3% of all adverse event reports for NORGESTIMATE AND ETHINYL ESTRADIOL, making it a notable side effect.
If you experience pulmonary embolism while taking NORGESTIMATE AND ETHINYL ESTRADIOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.